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Auto-inflammatory diseases are a rapidly moving field,
where the description of new entities, the understanding
of the pathogenesis and the treatment has shown impor-
tant progress in the past years. This group of conditions
include monogenic auto-inflammatory diseases, like FMF,
CAPS, TRAPS and MKD, and non-monogenic auto-
inflammatory diseases, like PFAPA, SoJIA, CRMO, and
Behçet. The most common clinical feature is recurrent
fever and a pro-inflammatory cytokine, IL-1, is a key
molecule involved in the pathogenesis of these diseases.
The treatment aims to control chronic inflammation and
blocking agents of IL-1 have shown a great efficacy in
most of these diseases.
The aim of the presentation is to make an update on
the diagnosis and the treatment and review the recent
recommendations elaborated by experts’ consensus
through the SHARE project.
Disclosure of interest
None declared.
Published: 17 September 2014
doi:10.1186/1546-0096-12-S1-I24
Cite this article as: Hofer: Auto-inflammatory diseases. Pediatric
Rheumatology 2014 12(Suppl 1):I24.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submitPediatric Rheumatology Romande, CHUV, University of Lausanne, Lausanne,
Switzerland
Hofer Pediatric Rheumatology 2014, 12(Suppl 1):I24
http://www.ped-rheum.com/content/12/S1/I24
© 2014 Hofer; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
